ClinicalTrials.gg
CompletedNCT02058160LixiLan-LUpdated May 9, 2017Results posted

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes

A Phase 3 interventional study of Insulin glargine/lixisenatide (HOE901/AVE0010) and Insulin glargine (HOE901) in Type 2 Diabetes, sponsored by Sanofi. Completed at 236 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-05-09.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
736
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 — 4 open to participants now, 6 under way, 1 of them phase 3. Insulin Glargine · Diabetes Mellitus, Type 2.

Enrollment
22nd of 175
736 · median 253
Started
2014
with 7 others
Phase 3
60 of 176
1 open now
Registered
111th of 176
by date
Lead sponsor
82 of 176
Sanofi

Among the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, this one is the 22nd largest by enrollment of the 175 interventional ones that give a count, is one of 8 that started in 2014, is one of 60 in phase 3, and was the 111th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About Insulin Glargine

Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

Primary Objective:

To demonstrate the superiority of the insulin glargine/lixisenatide fixed ratio combination (FRC) to insulin glargine in glycated hemoglobin (HbA1c) change from baseline to Week 30.

Secondary Objective:

To compare the overall efficacy and safety of insulin glargine/lixisenatide FRC to insulin glargine (with or without metformin) over a 30 week treatment period in participants with type 2 diabetes.

Read the detailed description

Maximum duration of approximately 39 weeks: an up to 8-week screening period, a 30-week randomized treatment period and 3 days post-treatment safety follow up period.

03

Conditions studied

  • Type 2 Diabetes
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion criteria :

  • Type 2 diabetes mellitus diagnosed at least 1 year before the screening visit.
  • Treatment with basal insulin for at least 6 months before the screening visit.
  • Stable basal insulin regimen (i.e. type of insulin and time/frequency of the injection) for at least 3 months before the screening visit.
  • Stable (plus/minus 20 percent) total daily basal insulin dose between 15 and 40 Units/day for at least 2 months prior to the screening visit.
  • For participants receiving basal insulin and 1 or 2 oral anti-diabetic drugs (OADs): the OAD dose(s) must be stable during the 3 months before the screening visit. The OADs could be 1 to 2 out of:

    • metformin (more than or equal to 1500 mg/day or maximal tolerated dose),
    • a sulfonylurea,
    • a glinide,
    • a dipeptidyl-peptidase-4 inhibitor,
    • a sodium glucose co-transporter 2 inhibitor,
  • Fasting Plasma Glucose (FPG) less than or equal to 180 mg/dL(10.0 mmol/L) at screening visit for participants receiving basal insulin in combination with 2 OADs or with 1 OAD other than metformin; FPG less than or equal to 200 mg/dL (11.1 mmol/L) at screening visit for participants on basal insulin only or basal insulin plus metformin at screening visit.
  • Signed written .

Exclusion criteria:

  • Age under legal age of adulthood at screening visit.
  • at screening visit less than 7.5% or above 10%.
  • Pregnancy or lactation, women of with no effective method.
  • Use of other oral or injectable glucose-lowering agents than stated in the inclusion criteria in a period of 3 months prior to screening.
  • Previous use of insulin other than basal insulin eg, prandial or pre-mixed insulin, in the year prior to screening. Note: Short term treatment (≤10 days) due to intercurrent illness is allowed.
  • History discontinuation of a previous treatment with Glucagon Like Peptide -1 Receptor Agonists for safety/tolerability or lack of efficacy.
  • Participant who had previously participated in any clinical trial with lixisenatide or the insulin glargine/lixisenatide FRC or had previously received lixisenatide.
  • Use of weight loss drugs within 3 months prior to screening visit.
  • Within the last 6 months prior to screening visit: history of stroke, myocardial infarction, unstable angina, or heart failure requiring hospitalization. Planned coronary, carotid or peripheral artery revascularisation procedures to be performed during the study period.
  • History of pancreatitis (unless pancreatitis was related to gallstones and cholecystectomy was already performed), chronic pancreatitis, pancreatitis during a previous treatment with incretin therapies, pancreatectomy, stomach/gastric surgery.
  • Personal or immediate family history of medullary thyroid cancer (MTC) or genetic conditions that predispose to MTC (eg, multiple endocrine neoplasia syndromes).
  • Uncontrolled or inadequately controlled hypertension (systolic blood pressure above 180 mmHg or diastolic blood pressure above 95 mmHg) at screening visit.
  • At screening visit, (BMI) less than or equal to 20 or above 40 kg/m\^2.
  • At screening visit amylase and/or lipase more than 3 times the (ULN) laboratory range.
  • At screening visit (ALT) or alkaline phosphatase (AST) more than 3 ULN.
  • At screening visit calcitonin above or equal to 20 pg/mL (5.9 pmol/L).
  • Any to metformin use, according to local labeling, if the participant was taking metformin.
  • Participant who had a renal function impairment with less than 30 mL/min (using the Cockcroft and Gault formula) or end-stage renal disease for participants, not treated with metformin.

Exclusion criteria for randomization:

  • HbA1c less than 7% or above 10% .
  • Mean fasting SMPG calculated from the self-measurements for 7 days the week before randomization visit was above 140 mg/dL (7.8 mmol/L).
  • Average insulin glargine daily dose less than 20 Units or above 50 Units (in the week before randomization visit).
  • Amylase and/or lipase more than 3 ULN .

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
736 participants (actual)

Study arms

  • Experimental
    Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC)

    FRC once daily (QD) for 30 weeks. Dose individually adjusted.

    Drug: Insulin glargine/lixisenatide (HOE901/AVE0010) · Drug: Metformin (Background Drug)

  • Active comparator
    Insulin glargine

    Insulin glargine 100 U/mL QD for 30 weeks. Dose individually adjusted.

    Drug: Insulin glargine (HOE901) · Drug: Metformin (Background Drug)

Interventions

  • DrugInsulin glargine/lixisenatide (HOE901/AVE0010)

    Drug pages: Insulin Glargine · Lixisenatide

    Insulin glargine/lixisenatide FRC was self-administered by subcutaneous (SC) injection within 1 hour before breakfast using one of 2 SoloStar® pen-injectors: Pen A (ratio of 2 Units (U) of insulin glargine U 100:1 mcg of lixisenatide) or Pen B (ratio of 3 U of insulin glargine U 100:1 mcg of lixisenatide). After run-in, the FRC was initiated at a dose of either 20 U/10 mcg with Pen A or 30 U/10 mcg with Pen B, depending on participant's dose of Insulin glargine on the day prior to randomization. Dose was adjusted weekly to reach and maintain fasting self-monitored plasma glucose (SMPG) of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L). Pen A was used for administration of doses up to 40 U/20 mcg and Pen B for administration of doses from 30 U/10 mcg up to 60 U/20 mcg.

  • Insulin glargine was self-administered QD by SC injection at approximately the same time every day. After screening, eligible participants entered 6 week run-in phase during which they were switched (if necessary) to insulin glargine and dose was stabilized. The first dose after randomization was same as the one administered on the day prior to randomization and then dose was adjusted weekly to reach and maintain fasting SMPG of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L).

    Also known as: Lantus

  • Pharmaceutical form: Tablet; Route of administration: Oral administration

06

What researchers measure

Primary outcomes

  1. Change in Glycated Hemoglobin (HbA1c) From Baseline to Week 30

    Change in HbA1c was calculated by subtracting baseline value from Week 30 value.

    Time frame: Baseline, Week 30

Secondary outcomes

  1. Percentage of Participants With HbA1c <7.0% or ≤6.5% at Week 30

    Time frame: Week 30

  2. Change in 2-hour Plasma Blood Glucose Excursion From Baseline to Week 30

    Plasma glucose excursion = 2-hour postprandial glucose (PPG) minus plasma glucose value obtained 30 minutes prior to the start of the meal and before investigational medicinal product (IMP) administration, if IMP was injected before breakfast. Change in plasma glucose excursions was calculated by subtracting baseline value from Week 30 value.

    Time frame: Baseline, Week 30

  3. Change in Body Weight From Baseline to Week 30

    Change in body weight was calculated by subtracting baseline value from Week 30 value.

    Time frame: Baseline, Week 30

  4. Mean Change in 7-point Self-monitored Plasma Glucose (SMPG) Profile From Baseline to Week 30

    Participants recorded a 7-point plasma glucose profile measured before and 2-hours after each meal and at bedtime, two times in a week before baseline, before visit Week 12 and before visit Week 30 and the average value across the profiles performed in the week before a visit for the 7 time points was calculated. Change in average 7 point SMPG was calculated by subtracting baseline value from Week 30 value. The analysis included all scheduled measurements obtained during the study. The missing data was handled by mixed effect model with repeated measures (MMRM) approach.

    Time frame: Baseline, Week 30

  5. Percentage of Participants Reaching HbA1c <7.0% With No Body Weight Gain at Week 30

    Time frame: Week 30

  6. Change in Daily Insulin Glargine Dose From Baseline to Week 30

    Time frame: Baseline, Week 30

  7. Percentage of Participants Reaching HbA1c <7.0% With No Body Weight Gain at Week 30 and No Documented Symptomatic Hypoglycemia (Plasma Glucose [PG] ≤ 70 mg/dL [3.9 mmol/L]) During 30-Week Treatment Period

    Documented symptomatic hypoglycemia was an event during which typical symptoms of hypoglycemia were accompanied by a measured plasma glucose concentration of ≤70 mg/dL (3.9 mmol/L).

    Time frame: Baseline up to Week 30

  8. Change in FPG From Baseline to Week 30

    Change in FPG was calculated by subtracting baseline value from Week 30 value.

    Time frame: Baseline, Week 30

  9. Change in 2-hour PPG From Baseline to Week 30

    Change in PPG was calculated by subtracting baseline value from Week 30 value.

    Time frame: Baseline, Week 30

  10. Percentage of Participants Reaching HbA1c <7.0% With No Documented Symptomatic Hypoglycemia (PG ≤ 70 mg/dL [3.9 mmol/L]) During 30-Week Treatment Period

    Documented symptomatic hypoglycemia was an event during which typical symptoms of hypoglycemia were accompanied by a measured plasma glucose concentration of ≤70 mg/dL (3.9 mmol/L).

    Time frame: Baseline up to Week 30

  11. Percentage of Participants Requiring Rescue Therapy During 30-Week Treatment Period

    Routine fasting SMPG and central laboratory FPG (and HbA1c after Week 12) values were used to determine the requirement of rescue medication. If fasting SMPG value exceeded the specified limit for 3 consecutive days, the central laboratory FPG (and HbA1c after Week 12) were performed. Threshold values - from Week 8 to Week 12: fasting SMPG/FPG \>240 mg/dL (13.3 mmol/L), and from Week 12 to Week 30: fasting SMPG/FPG \>200 mg/dL (11.1 mmol/L) or HbA1c \>8%.

    Time frame: Baseline up to Week 30

  12. Number of Documented Symptomatic Hypoglycemia Events Per Subject-Year

    Documented symptomatic hypoglycemia was an event during which typical symptoms of hypoglycemia were accompanied by a measured plasma glucose concentration of ≤70 mg/dL (3.9 mmol/L).

    Time frame: First dose of study drug up to 1 day after the last dose administration (median treatment exposure 211 days [FRC], 210 days [Insulin glargine])

  13. Percentage of Participants With Documented Symptomatic Hypoglycemia

    Documented symptomatic hypoglycemia was an event during which typical symptoms of hypoglycemia were accompanied by a measured plasma glucose concentration of ≤70 mg/dL (3.9 mmol/L).

    Time frame: First dose of study drug up to 1 day after the last dose administration (median treatment exposure 211 days [FRC], 210 days [Insulin glargine])

  14. Percentage of Participants With Severe Symptomatic Hypoglycemia

    Severe symptomatic hypoglycemia was an event requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Plasma glucose measurements might not had been available during such an event, but neurological recovery attributable to the restoration of plasma glucose to normal was considered sufficient evidence that the event had been induced by a low plasma glucose concentration. Severe symptomatic hypoglycemia included all episodes in which neurological impairment was severe enough to prevent self-treatment, and which were thus thought to place participants at risk for injury to themselves or others.

    Time frame: First dose of study drug up to 1 day after the last dose administration (median treatment exposure 211 days [FRC], 210 days [Insulin glargine])

07

Results

Posted Feb 10, 2017

Participant flow

The study was conducted at 236 centers in 18 countries. A total of 1930 participants were screened between January 27, 2014 and October 15, 2014. 912 participants were not eligible for run-in-phase mainly due to glycated hemoglobin (HbA1c) value being out of the protocol defined range.

Participant flow — Overall Study
MilestoneInsulin Glargine/Lixisenatide Fixed Ratio Combination (FRC)Insulin Glargine
Started367369
Treated365365
Completed336355
Not completed3114
Withdrew: Randomized but not treated24
Withdrew: Poor compliance to protocol41
Withdrew: Adverse event123
Withdrew: Lost to follow-up10
Withdrew: Other than specified above126

Outcome measures

PrimaryChange in Glycated Hemoglobin (HbA1c) From Baseline to Week 30

Change in HbA1c was calculated by subtracting baseline value from Week 30 value.

Time frame:
Baseline, Week 30
Reported as:
Least squares mean · percentage of HbA1c
Change in Glycated Hemoglobin (HbA1c) From Baseline to Week 30
percentage of HbA1cInsulin Glargine/Lixisenatide Fixed Ratio CombinationInsulin Glargine
Change in Glycated Hemoglobin (HbA1c) From Baseline to Week 30-1.13 ± 0.057-0.62 ± 0.055
Statistical analysis
  • Insulin Glargine/Lixisenatide Fixed Ratio Combination vs Insulin Glargine · Mixed Models Analysis · p = <0.0001 (Threshold for significance at 0.05 level.) · Least square (ls) mean difference: -0.52 · 95% CI -0.633 to -0.397Insulin Glargine/Lixisenatide FRC vs Insulin Glargine
SecondaryPercentage of Participants With HbA1c <7.0% or ≤6.5% at Week 30
Time frame:
Week 30
Reported as:
Number · percentage of participants
Percentage of Participants With HbA1c <7.0% or ≤6.5% at Week 30
percentage of participantsInsulin Glargine/Lixisenatide Fixed Ratio CombinationInsulin Glargine
HbA1c <7.0%54.929.6
HbA1c ≤ 6.5%33.914.2
Statistical analysis
  • Insulin Glargine/Lixisenatide Fixed Ratio Combination vs Insulin Glargine · Cochran-Mantel-Haenszel · p = <0.0001 (Threshold for significance at 0.05 level.) · Difference in percentage: 25.52 · 95% CI 18.94 to 32.10HbA1c \<7.0%: Insulin Glargine/Lixisenatide FRC vs Insulin Glargine
  • Insulin Glargine/Lixisenatide Fixed Ratio Combination vs Insulin Glargine · Cochran-Mantel-Haenszel · p = <0.0001 · Difference in percentage: 19.76 · 95% CI 13.90 to 25.62HbA1c ≤6.5%: Insulin Glargine/Lixisenatide FRC vs Insulin Glargine
SecondaryChange in 2-hour Plasma Blood Glucose Excursion From Baseline to Week 30

Plasma glucose excursion = 2-hour postprandial glucose (PPG) minus plasma glucose value obtained 30 minutes prior to the start of the meal and before investigational medicinal product (IMP) administration, if IMP was injected before breakfast. Change in plasma glucose excursions was calculated by subtracting baseline value from Week 30 value.

Time frame:
Baseline, Week 30
Reported as:
Least squares mean · mmol/L
Change in 2-hour Plasma Blood Glucose Excursion From Baseline to Week 30
mmol/LInsulin Glargine/Lixisenatide Fixed Ratio CombinationInsulin Glargine
Change in 2-hour Plasma Blood Glucose Excursion From Baseline to Week 30-3.9 ± 0.285-0.47 ± 0.274
Statistical analysis
  • Insulin Glargine/Lixisenatide Fixed Ratio Combination vs Insulin Glargine · ANCOVA · p = <0.0001 (Threshold for significance at 0.05 level.) · Ls mean difference: -3.43 · 95% CI -3.925 to -2.939Insulin Glargine/Lixisenatide FRC vs Insulin Glargine
SecondaryChange in Body Weight From Baseline to Week 30

Change in body weight was calculated by subtracting baseline value from Week 30 value.

Time frame:
Baseline, Week 30
Reported as:
Least squares mean · kg
Change in Body Weight From Baseline to Week 30
kgInsulin Glargine/Lixisenatide Fixed Ratio CombinationInsulin Glargine
Change in Body Weight From Baseline to Week 30-0.67 ± 0.1810.7 ± 0.178
Statistical analysis
  • Insulin Glargine/Lixisenatide Fixed Ratio Combination vs Insulin Glargine · Mixed Models Analysis · p = <0.0001 (Threshold for significance at 0.05 level.) · Ls mean difference: -1.37 · 95% CI -1.808 to -0.93Insulin Glargine/Lixisenatide FRC vs Insulin Glargine
SecondaryMean Change in 7-point Self-monitored Plasma Glucose (SMPG) Profile From Baseline to Week 30

Participants recorded a 7-point plasma glucose profile measured before and 2-hours after each meal and at bedtime, two times in a week before baseline, before visit Week 12 and before visit Week 30 and the average value across the profiles performed in the week before a visit for the 7 time points was calculated. Change in average 7 point SMPG was calculated by subtracting baseline value from Week 30 value. The analysis included all scheduled measurements obtained during the study. The missing data was handled by mixed effect model with repeated measures (MMRM) approach.

Time frame:
Baseline, Week 30
Reported as:
Least squares mean · mmol/L
Mean Change in 7-point Self-monitored Plasma Glucose (SMPG) Profile From Baseline to Week 30
mmol/LInsulin Glargine/Lixisenatide Fixed Ratio CombinationInsulin Glargine
Mean Change in 7-point Self-monitored Plasma Glucose (SMPG) Profile From Baseline to Week 30-1.5 ± 0.137-0.6 ± 0.13
Statistical analysis
  • Insulin Glargine/Lixisenatide Fixed Ratio Combination vs Insulin Glargine · Mixed Models Analysis · p = <0.0001 (Threshold for significance at 0.05 level.) · Ls mean difference: -0.9 · 95% CI -1.154 to -0.64Insulin Glargine/Lixisenatide FRC vs Insulin Glargine
SecondaryPercentage of Participants Reaching HbA1c <7.0% With No Body Weight Gain at Week 30
Time frame:
Week 30
Reported as:
Number · percentage of participants
Percentage of Participants Reaching HbA1c <7.0% With No Body Weight Gain at Week 30
percentage of participantsInsulin Glargine/Lixisenatide Fixed Ratio CombinationInsulin Glargine
Percentage of Participants Reaching HbA1c <7.0% With No Body Weight Gain at Week 3034.213.4
Statistical analysis
  • Insulin Glargine/Lixisenatide Fixed Ratio Combination vs Insulin Glargine · Cochran-Mantel-Haenszel · p = <0.0001 (Threshold for significance at 0.05 level.) · Difference in percentage: 20.82 · 95% CI 14.98 to 26.66Insulin Glargine/Lixisenatide FRC vs Insulin Glargine
SecondaryChange in Daily Insulin Glargine Dose From Baseline to Week 30
Time frame:
Baseline, Week 30
Reported as:
Least squares mean · Units (U)
Change in Daily Insulin Glargine Dose From Baseline to Week 30
Units (U)Insulin Glargine/Lixisenatide Fixed Ratio CombinationInsulin Glargine
Change in Daily Insulin Glargine Dose From Baseline to Week 3010.64 ± 0.60110.89 ± 0.587
Statistical analysis
  • Insulin Glargine/Lixisenatide Fixed Ratio Combination vs Insulin Glargine · Mixed Models Analysis · p = 0.7362 (Threshold for significance at 0.05 level.) · Ls mean difference: -0.26 · 95% CI -1.762 to 1.246Insulin Glargine/Lixisenatide FRC vs Insulin Glargine
SecondaryPercentage of Participants Reaching HbA1c <7.0% With No Body Weight Gain at Week 30 and No Documented Symptomatic Hypoglycemia (Plasma Glucose [PG] ≤ 70 mg/dL [3.9 mmol/L]) During 30-Week Treatment Period

Documented symptomatic hypoglycemia was an event during which typical symptoms of hypoglycemia were accompanied by a measured plasma glucose concentration of ≤70 mg/dL (3.9 mmol/L).

Time frame:
Baseline up to Week 30
Reported as:
Number · percentage of participants
Percentage of Participants Reaching HbA1c <7.0% With No Body Weight Gain at Week 30 and No Documented Symptomatic Hypoglycemia (Plasma Glucose [PG] ≤ 70 mg/dL [3.9 mmol/L]) During 30-Week Treatment Period
percentage of participantsInsulin Glargine/Lixisenatide Fixed Ratio CombinationInsulin Glargine
Percentage of Participants Reaching HbA1c <7.0% With No Body Weight Gain at Week 30 and No Documented Symptomatic Hypoglycemia (Plasma Glucose [PG] ≤ 70 mg/dL [3.9 mmol/L]) During 30-Week Treatment Period19.99.0
SecondaryChange in FPG From Baseline to Week 30

Change in FPG was calculated by subtracting baseline value from Week 30 value.

Time frame:
Baseline, Week 30
Reported as:
Least squares mean · mmol/L
Change in FPG From Baseline to Week 30
mmol/LInsulin Glargine/Lixisenatide Fixed Ratio CombinationInsulin Glargine
Change in FPG From Baseline to Week 30-0.35 ± 0.142-0.46 ± 0.138
SecondaryChange in 2-hour PPG From Baseline to Week 30

Change in PPG was calculated by subtracting baseline value from Week 30 value.

Time frame:
Baseline, Week 30
Reported as:
Least squares mean · mmol/L
Change in 2-hour PPG From Baseline to Week 30
mmol/LInsulin Glargine/Lixisenatide Fixed Ratio CombinationInsulin Glargine
Change in 2-hour PPG From Baseline to Week 30-4.72 ± 0.322-1.39 ± 0.31
SecondaryPercentage of Participants Reaching HbA1c <7.0% With No Documented Symptomatic Hypoglycemia (PG ≤ 70 mg/dL [3.9 mmol/L]) During 30-Week Treatment Period

Documented symptomatic hypoglycemia was an event during which typical symptoms of hypoglycemia were accompanied by a measured plasma glucose concentration of ≤70 mg/dL (3.9 mmol/L).

Time frame:
Baseline up to Week 30
Reported as:
Number · percentage of participants
Percentage of Participants Reaching HbA1c <7.0% With No Documented Symptomatic Hypoglycemia (PG ≤ 70 mg/dL [3.9 mmol/L]) During 30-Week Treatment Period
percentage of participantsInsulin Glargine/Lixisenatide Fixed Ratio CombinationInsulin Glargine
Percentage of Participants Reaching HbA1c <7.0% With No Documented Symptomatic Hypoglycemia (PG ≤ 70 mg/dL [3.9 mmol/L]) During 30-Week Treatment Period31.718.6
SecondaryPercentage of Participants Requiring Rescue Therapy During 30-Week Treatment Period

Routine fasting SMPG and central laboratory FPG (and HbA1c after Week 12) values were used to determine the requirement of rescue medication. If fasting SMPG value exceeded the specified limit for 3 consecutive days, the central laboratory FPG (and HbA1c after Week 12) were performed. Threshold values - from Week 8 to Week 12: fasting SMPG/FPG \>240 mg/dL (13.3 mmol/L), and from Week 12 to Week 30: fasting SMPG/FPG \>200 mg/dL (11.1 mmol/L) or HbA1c \>8%.

Time frame:
Baseline up to Week 30
Reported as:
Number · percentage of participants
Percentage of Participants Requiring Rescue Therapy During 30-Week Treatment Period
percentage of participantsInsulin Glargine/Lixisenatide Fixed Ratio CombinationInsulin Glargine
Percentage of Participants Requiring Rescue Therapy During 30-Week Treatment Period2.76
SecondaryNumber of Documented Symptomatic Hypoglycemia Events Per Subject-Year

Documented symptomatic hypoglycemia was an event during which typical symptoms of hypoglycemia were accompanied by a measured plasma glucose concentration of ≤70 mg/dL (3.9 mmol/L).

Time frame:
First dose of study drug up to 1 day after the last dose administration (median treatment exposure 211 days [FRC], 210 days [Insulin glargine])
Reported as:
Number · events per subject-year
Number of Documented Symptomatic Hypoglycemia Events Per Subject-Year
events per subject-yearInsulin Glargine/Lixisenatide Fixed Ratio CombinationInsulin Glargine
Number of Documented Symptomatic Hypoglycemia Events Per Subject-Year3.034.22
SecondaryPercentage of Participants With Documented Symptomatic Hypoglycemia

Documented symptomatic hypoglycemia was an event during which typical symptoms of hypoglycemia were accompanied by a measured plasma glucose concentration of ≤70 mg/dL (3.9 mmol/L).

Time frame:
First dose of study drug up to 1 day after the last dose administration (median treatment exposure 211 days [FRC], 210 days [Insulin glargine])
Reported as:
Number · percentage of participants
Percentage of Participants With Documented Symptomatic Hypoglycemia
percentage of participantsInsulin Glargine/Lixisenatide Fixed Ratio CombinationInsulin Glargine
Percentage of Participants With Documented Symptomatic Hypoglycemia4042.5
SecondaryPercentage of Participants With Severe Symptomatic Hypoglycemia

Severe symptomatic hypoglycemia was an event requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Plasma glucose measurements might not had been available during such an event, but neurological recovery attributable to the restoration of plasma glucose to normal was considered sufficient evidence that the event had been induced by a low plasma glucose concentration. Severe symptomatic hypoglycemia included all episodes in which neurological impairment was severe enough to prevent self-treatment, and which were thus thought to place participants at risk for injury to themselves or others.

Time frame:
First dose of study drug up to 1 day after the last dose administration (median treatment exposure 211 days [FRC], 210 days [Insulin glargine])
Reported as:
Number · percentage of participants
Percentage of Participants With Severe Symptomatic Hypoglycemia
percentage of participantsInsulin Glargine/Lixisenatide Fixed Ratio CombinationInsulin Glargine
Percentage of Participants With Severe Symptomatic Hypoglycemia1.10.3

Adverse events

Collected over All Adverse Events (AE) were collected from signature of the informed consent form up to the final visit (Week 30) regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Insulin Glargine/Lixisenatide Fixed Ratio Combination—20/365 (5.5%)81/365 (22.2%)
Insulin Glargine—18/365 (4.9%)42/365 (11.5%)
Most frequent serious events
Showing 10 of 33
Most frequent serious events
EventInsulin Glargine/Lixisenatide Fixed Ratio CombinationInsulin Glargine
HypoglycaemiaMetabolism and nutrition disorders2/3651/365
Hypoglycaemic unconsciousnessNervous system disorders2/3650/365
Acute myocardial infarctionCardiac disorders2/3650/365
Angina unstableCardiac disorders2/3650/365
Non-cardiac chest painGeneral disorders0/3652/365
PneumoniaInfections and infestations1/3651/365
OsteomyelitisInfections and infestations0/3651/365
Wound infectionInfections and infestations0/3651/365
Benign breast neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/3650/365
Benign gastric neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/3650/365
Most frequent other events
Most frequent other events
EventInsulin Glargine/Lixisenatide Fixed Ratio CombinationInsulin Glargine
NauseaGastrointestinal disorders38/3652/365
NasopharyngitisInfections and infestations32/36532/365
HeadacheNervous system disorders21/36510/365

Baseline characteristics

Age, Continuous
Age, Continuous(years)Insulin Glargine/Lixisenatide Fixed Ratio CombinationInsulin GlargineTotal
Mean59.6 ± 9.460.3 ± 8.760.0 ± 9.1
Sex: Female, Male
Sex: Female, Male(Participants)Insulin Glargine/Lixisenatide Fixed Ratio CombinationInsulin GlargineTotal
Female202190392
Male165179344
Race
Race(Participants)Insulin Glargine/Lixisenatide Fixed Ratio CombinationInsulin GlargineTotal
Caucasian337338675
Black172138
Asian/Oriental12820
Other123
Ethnicity
Ethnicity(Participants)Insulin Glargine/Lixisenatide Fixed Ratio CombinationInsulin GlargineTotal
Hispanic6666132
Not Hispanic301303604
OAD Use
OAD Use(Participants)Insulin Glargine/Lixisenatide Fixed Ratio CombinationInsulin GlargineTotal
Yes349350699
No181937
OAD Use at Screening by Class
OAD Use at Screening by Class(Participants)Insulin Glargine/Lixisenatide Fixed Ratio CombinationInsulin GlargineTotal
Metformin170190360
Sulfonylurea161430
Sodium glucose co-transporter 2 (SGLT-2) inhibitor011
Dipeptidyl-peptidase 4 (DPP-4) inhibitor246
Glinide112
Metformin + Sulfonylurea137118255
Metformin + DPP-4 inhibitor201838
Metfomrin + Glinide235
Sulfonylurea + DPP-4 inhibitor112
None181937
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)Insulin Glargine/Lixisenatide Fixed Ratio CombinationInsulin GlargineTotal
Mean31.33 ± 4.2530.96 ± 4.1531.14 ± 4.20
Duration of Diabetes
Duration of Diabetes(years)Insulin Glargine/Lixisenatide Fixed Ratio CombinationInsulin GlargineTotal
Mean12.02 ± 6.6412.13 ± 6.8512.08 ± 6.74

4 further baseline measures are reported on the registry.

08

Study locations

236 sites
  • Investigational Site Number 840607
    Birmingham, Alabama 35205, United States
  • Investigational Site Number 840570
    Sun City, Arizona 85351, United States
  • Investigational Site Number 840562
    Tempe, Arizona, United States
  • Investigational Site Number 840577
    Tucson, Arizona 85723, United States
  • Investigational Site Number 840517
    Little Rock, Arkansas 72205, United States
  • Investigational Site Number 840537
    Little Rock, Arkansas 72205, United States
  • Investigational Site Number 840568
    Bell Gardens, California 90201, United States
  • Investigational Site Number 840550
    Chino, California 91710, United States
  • Investigational Site Number 840529
    Chula Vista, California 91911, United States
  • Investigational Site Number 840623
    Corona, California 92879, United States
  • Investigational Site Number 840566
    Fresno, California 93720, United States
  • Investigational Site Number 840552
    Greenbrae, California 94904, United States
  • Investigational Site Number 840578
    Lancaster, California 93534, United States
  • Investigational Site Number 840626
    Los Angeles, California 90017, United States
  • Investigational Site Number 840581
    Los Angeles, California 90057, United States
  • Investigational Site Number 840621
    Mission Viejo, California 92691, United States
  • Investigational Site Number 840511
    Northridge, California 91325, United States
  • Investigational Site Number 840573
    Palm Springs, California 92262, United States
  • Investigational Site Number 840559
    Port Hueneme, California 93041, United States
  • Investigational Site Number 840536
    San Ramon, California 94583, United States
  • Investigational Site Number 840567
    Santa Ana, California 92704, United States
  • Investigational Site Number 840569
    Tarzana, California 91356, United States
  • Investigational Site Number 840572
    West Hills, California 91345, United States
  • Investigational Site Number 840582
    Aurora, Colorado 80045, United States
  • Investigational Site Number 840509
    Denver, Colorado 80246, United States
  • Investigational Site Number 840549
    Wilmington, Delaware 19713, United States
  • Investigational Site Number 840510
    Miami, Florida 33156-7563, United States
  • Investigational Site Number 840521
    New Port Richey, Florida 34652, United States
  • Investigational Site Number 840602
    Ocala, Florida 34471, United States
  • Investigational Site Number 840538
    Ocoee, Florida 34761, United States
  • Investigational Site Number 840534
    Palm Harbor, Florida 34684, United States
  • Investigational Site Number 840594
    Atlanta, Georgia 30322, United States
  • Investigational Site Number 840614
    Columbus, Georgia 31904, United States
  • Investigational Site Number 840501
    Lawrenceville, Georgia 30046, United States
  • Investigational Site Number 840525
    Roswell, Georgia 30076, United States
  • Investigational Site Number 840588
    Idaho Falls, Idaho 83404, United States
  • Investigational Site Number 840580
    Arlington Heights, Illinois 60005, United States
  • Investigational Site Number 840519
    Chicago, Illinois 60607, United States
  • Investigational Site Number 840612
    Chicago, Illinois 60616, United States
  • Investigational Site Number 840556
    Springfield, Illinois 62704, United States
  • Investigational Site Number 840543
    Avon, Indiana 46123, United States
  • Investigational Site Number 840565
    Evansville, Indiana 47713, United States
  • Investigational Site Number 840585
    Evansville, Indiana 47714, United States
  • Investigational Site Number 840615
    Evansville, Indiana 47714, United States
  • Investigational Site Number 840563
    Indianapolis, Indiana 46202, United States
  • Investigational Site Number 840507
    Indianapolis, Indiana 46260, United States
  • Investigational Site Number 840516
    Louisville, Kentucky 40213, United States
  • Investigational Site Number 840595
    Lewiston, Maine 04240, United States
  • Investigational Site Number 840520
    Baltimore, Maryland 21237, United States
  • Investigational Site Number 840560
    Baltimore, Maryland 21237, United States
  • Investigational Site Number 840522
    Rockville, Maryland 20852, United States
  • Investigational Site Number 840505
    Dearborn, Michigan 48124, United States
  • Investigational Site Number 840575
    Flint, Michigan 48504, United States
  • Investigational Site Number 840564
    Minneapolis, Minnesota 55416, United States
  • Investigational Site Number 840558
    Butte, Montana 59701, United States
  • Investigational Site Number 840506
    Omaha, Nebraska 68131, United States
  • Investigational Site Number 840600
    Henderson, Nevada 89074, United States
  • Investigational Site Number 840532
    Las Vegas, Nevada 89119, United States
  • Investigational Site Number 840599
    Las Vegas, Nevada 89148, United States
  • Investigational Site Number 840539
    Nashua, New Hampshire 03063, United States
  • Investigational Site Number 840576
    Albuquerque, New Mexico 87131, United States
  • Investigational Site Number 840583
    Jamaica, New York 11432, United States
  • Investigational Site Number 840531
    New Hyde Park, New York 11042, United States
  • Investigational Site Number 840557
    Syracuse, New York 13214-2016, United States
  • Investigational Site Number 840541
    Durham, North Carolina 27710, United States
  • Investigational Site Number 840604
    Greenville, North Carolina 27858, United States
  • Investigational Site Number 840540
    Hickory, North Carolina 28601, United States
  • Investigational Site Number 840513
    Morehead City, North Carolina 28557, United States
  • Investigational Site Number 840592
    Salisbury, North Carolina 28144, United States
  • Investigational Site Number 840535
    Wilmington, North Carolina 28401, United States
  • Investigational Site Number 840515
    Winston-Salem, North Carolina 27103, United States
  • Investigational Site Number 840579
    Columbus, Ohio 43213, United States
  • Investigational Site Number 840524
    Dayton, Ohio 45439, United States
  • Investigational Site Number 840503
    Maumee, Ohio 43537, United States
  • Investigational Site Number 840618
    Eugene, Oregon 97404, United States
  • Investigational Site Number 840610
    Philadelphia, Pennsylvania 19107, United States
  • Investigational Site Number 840551
    Smithfield, Pennsylvania 15478, United States
  • Investigational Site Number 840584
    Tipton, Pennsylvania 16684, United States
  • Investigational Site Number 840622
    Charleston, South Carolina 29407, United States
  • Investigational Site Number 840611
    Rapid City, South Dakota 57701, United States
  • Investigational Site Number 840605
    Amarillo, Texas 79106, United States
  • Investigational Site Number 840553
    Austin, Texas 78731, United States
  • Investigational Site Number 840598
    Austin, Texas 78731, United States
  • Investigational Site Number 840502
    Corpus Christi, Texas 78404, United States
  • Investigational Site Number 840601
    Dallas, Texas 75208, United States
  • Investigational Site Number 840586
    Dallas, Texas 75216, United States
  • Investigational Site Number 840547
    Dallas, Texas 75230, United States
  • Investigational Site Number 840530
    Dallas, Texas 75231, United States
  • Investigational Site Number 840545
    Dallas, Texas 75246, United States
  • Investigational Site Number 840554
    Edinburg, Texas 78539, United States
  • Investigational Site Number 840544
    Houston, Texas 77030, United States
  • Investigational Site Number 840514
    Hurst, Texas 76054, United States
  • Investigational Site Number 840617
    N Richland Hill, Texas 76180, United States
  • Investigational Site Number 840512
    Draper, Utah 84020, United States
  • Investigational Site Number 840591
    Murray, Utah 84123, United States
  • Investigational Site Number 840526
    Ogden, Utah 84405, United States
  • Investigational Site Number 840597
    Orem, Utah 84058, United States
  • Investigational Site Number 840590
    Salt Lake City, Utah 84102, United States
  • Investigational Site Number 840613
    Burlington, Vermont 05401, United States
  • Investigational Site Number 840504
    Chesapeake, Virginia 23321, United States

Showing the first 100 of 236 sites across 18 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Aroda VR, Rosenstock J, Wysham C, Unger J, Bellido D, Gonzalez-Galvez G, Takami A, Guo H, Niemoeller E, Souhami E, Bergenstal RM; LixiLan-L Trial Investigators. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial. Diabetes Care. 2016 Nov;39(11):1972-1980. doi: 10.2337/dc16-1495. Epub 2016 Sep 20. Erratum In: Diabetes Care. 2017 Jun;40(6):809. doi: 10.2337/dc17-er06d. PubMed 27650977 ↗
  • Tabak AG, Anderson J, Aschner P, Liu M, Saremi A, Stella P, Tinahones FJ, Wysham C, Meier JJ. Efficacy and Safety of iGlarLixi, Fixed-Ratio Combination of Insulin Glargine and Lixisenatide, Compared with Basal-Bolus Regimen in Patients with Type 2 Diabetes: Propensity Score Matched Analysis. Diabetes Ther. 2020 Jan;11(1):305-318. doi: 10.1007/s13300-019-00735-7. Epub 2019 Dec 17. PubMed 31848983 ↗
  • Blonde L, Bailey TS, Chao J, Dex TA, Frias JP, Meneghini LF, Roberts M, Aroda VR. Clinical Characteristics and Glycemic Outcomes of Patients with Type 2 Diabetes Requiring Maximum Dose Insulin Glargine/Lixisenatide Fixed-Ratio Combination or Insulin Glargine in the LixiLan-L Trial. Adv Ther. 2019 Sep;36(9):2310-2326. doi: 10.1007/s12325-019-01033-1. Epub 2019 Jul 29. PubMed 31359368 ↗
  • Dailey G, Bajaj HS, Dex T, Groleau M, Stager W, Vinik A. Post hoc efficacy and safety analysis of insulin glargine/lixisenatide fixed- ratio combination in North American patients compared with the rest of world. BMJ Open Diabetes Res Care. 2019 Mar 21;7(1):e000581. doi: 10.1136/bmjdrc-2018-000581. eCollection 2019. PubMed 31114694 ↗
  • Schmider W, Belder R, Lee M, Niemoeller E, Souhami E, Frias JP. Impact of dose capping in insulin glargine/lixisenatide fixed-ratio combination trials in patients with type 2 diabetes. Curr Med Res Opin. 2019 Jun;35(6):1081-1089. doi: 10.1080/03007995.2018.1558852. Epub 2019 Jan 11. PubMed 30550345 ↗
  • Zisman A, Dex T, Roberts M, Saremi A, Chao J, Aroda VR. Bedtime-to-Morning Glucose Difference and iGlarLixi in Type 2 Diabetes: Post Hoc Analysis of LixiLan-L. Diabetes Ther. 2018 Oct;9(5):2155-2162. doi: 10.1007/s13300-018-0507-0. Epub 2018 Sep 14. Erratum In: Diabetes Ther. 2019 Feb;10(1):327. doi: 10.1007/s13300-018-0544-8. PubMed 30218434 ↗
  • Rosenstock J, Handelsman Y, Vidal J, Ampudia Blasco FJ, Giorgino F, Liu M, Perfetti R, Meier JJ. Propensity-score-matched comparative analyses of simultaneously administered fixed-ratio insulin glargine 100 U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes. Diabetes Obes Metab. 2018 Dec;20(12):2821-2829. doi: 10.1111/dom.13462. Epub 2018 Aug 13. PubMed 29974618 ↗
  • Trujillo JM, Roberts M, Dex T, Chao J, White J, LaSalle J. Low incidence of gastrointestinal adverse events over time with a fixed-ratio combination of insulin glargine and lixisenatide versus lixisenatide alone. Diabetes Obes Metab. 2018 Nov;20(11):2690-2694. doi: 10.1111/dom.13444. Epub 2018 Aug 21. PubMed 29923298 ↗
  • Niemoeller E, Souhami E, Wu Y, Jensen KH. iGlarLixi Reduces Glycated Hemoglobin to a Greater Extent Than Basal Insulin Regardless of Levels at Screening: Post Hoc Analysis of LixiLan-L. Diabetes Ther. 2018 Feb;9(1):373-382. doi: 10.1007/s13300-017-0336-6. Epub 2017 Nov 16. PubMed 29143919 ↗
  • Wysham C, Bonadonna RC, Aroda VR, Puig Domingo M, Kapitza C, Stager W, Yu C, Niemoeller E, Souhami E, Bergenstal RM; LixiLan-L trial investigators. Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) vs insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-L trial. Diabetes Obes Metab. 2017 Oct;19(10):1408-1415. doi: 10.1111/dom.12961. Epub 2017 Jun 8. PubMed 28386990 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2014, a primary completion of Jul 2015 and a completion of Jul 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2017, 1 year 7 months after primary completion. A results delay was requested in Jul 2016.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2014
First posted
Feb 7, 2014
Start
Jan 2014
Primary completionActual
Jul 2015
CompletionActual
Jul 2015
Results delay requested
Jul 1, 2016
Results first posted
Feb 10, 2017
Last update
May 9, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 9, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02058160
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Feb 7, 2014
Start date
Jan 2014
Primary completion
Jul 2015
Completion
Jul 2015
Results posted
Feb 10, 2017
Last update
May 9, 2017

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin Glargine · Lixisenatide

Start the discussion